Is Humira a biologic?
Yes. Humira (adalimumab) is a monoclonal antibody that targets tumor necrosis factor‑α. Because it is a protein produced by living cells, it is classified as a biologic drug. [1]
What makes a drug a biologic?
Biologics are medicines derived from living organisms or their products. They are usually proteins, antibodies, or nucleic acids, and they are produced by recombinant DNA technology or cell culture. Unlike small‑molecule drugs, which are chemically synthesized, biologics have complex structures that make them harder to manufacture and copy. [2]
How did Humira become a biologic drug?
AbbVie engineered a humanized antibody in a CHO (Chinese hamster ovary) cell line, then purified it for clinical use. The process required cell‑based expression systems and downstream purification steps that are characteristic of biologic development. [3]
When was Humira first approved and for what uses?
The FDA approved Humira in 2002 for rheumatoid arthritis. Since then it has gained approvals for Crohn’s disease, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and more. [4]
Who owns and markets Humira?
AbbVie holds the marketing rights and continues to produce Humira worldwide. [5]
Which patents protect Humira?
Key patents cover the adalimumab antibody sequence, its formulation, and the manufacturing process. DrugPatentWatch lists several patents that are expected to remain in force through the late 2020s, with the core exclusivity likely extending until about 2038. [6]
When might biosimilar versions of Humira appear?
Biosimilar approval depends on patent expirations, regulatory pathways, and market entry decisions. With core patents still in force, a biosimilar could enter the U.S. market roughly around 2033–2038, assuming no additional patent challenges delay entry. [7]
Why are other companies chasing Humira’s patents?
Because Humira is the top‑selling biologic for inflammatory diseases, a biosimilar could capture a large share of the market once it is allowed. That potential drives companies to file litigation or seek accelerated approval pathways. [8]
Are any Humira biosimilars already on the market?
A few biosimilars have been approved in the EU and other regions, such as Amjevita (adalimumab‑atto) and Cyltezo (adalimumab‑tpyb). In the United States, the first FDA‑approved biosimilar, Amjevita, entered the market in 2018, but it faces competition from patents still in force. [9]
How does the FDA regulate biologics like Humira?
The FDA requires a biologic license application (BLA) that includes detailed manufacturing, quality, and clinical data. Post‑marketing surveillance tracks safety signals and long‑term efficacy. [10]
What happens after Humira’s patents expire?
Once the patents lapse, other manufacturers can submit biosimilar BLAs. AbbVie typically monitors for biosimilar launch and may use strategic pricing, marketing, or limited‑use contracts to protect sales. The expiration also opens the door for generics of the active ingredient in some jurisdictions. [11]
---
Sources
1. https://drugpatentwatch.com/drugs/humira
2. https://drugpatentwatch.com/definitions/biologic
3. https://drugpatentwatch.com/companies/abbvie
4. https://drugpatentwatch.com/approved-drugs/humira
5. https://drugpatentwatch.com/companies/abbvie
6. https://drugpatentwatch.com/patents/humira
7. https://drugpatentwatch.com/biosimilars/humira
8. https://drugpatentwatch.com/industry-news/biologics
9. https://drugpatentwatch.com/biosimilars/amjevita
10. https://drugpatentwatch.com/regulation/fda-biologics
11. https://drugpatentwatch.com/market-analysis/biologics-exclusivity